Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams bought 17,052 shares of the company’s stock in a transaction dated Thursday, August 23rd. The stock was bought at an average cost of $1.63 per share, with a total value of $27,794.76. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website.

Gregg Williams also recently made the following trade(s):

  • On Monday, August 20th, Gregg Williams bought 4,110 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.57 per share, with a total value of $6,452.70.
  • On Friday, August 17th, Gregg Williams bought 7,800 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.56 per share, with a total value of $12,168.00.
  • On Wednesday, August 15th, Gregg Williams bought 3,247,362 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.55 per share, with a total value of $5,033,411.10.
  • On Monday, August 13th, Gregg Williams bought 7,000 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.60 per share, with a total value of $11,200.00.
  • On Thursday, August 9th, Gregg Williams bought 22,509 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.57 per share, with a total value of $35,339.13.
  • On Monday, August 6th, Gregg Williams bought 8,188 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.66 per share, with a total value of $13,592.08.
  • On Friday, July 27th, Gregg Williams bought 23,749 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.62 per share, with a total value of $38,473.38.
  • On Wednesday, July 25th, Gregg Williams bought 10,402 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.60 per share, with a total value of $16,643.20.
  • On Monday, July 23rd, Gregg Williams bought 24,476 shares of Second Sight Medical Products stock. The stock was bought at an average cost of $1.67 per share, with a total value of $40,874.92.
  • On Thursday, July 19th, Gregg Williams acquired 22,760 shares of Second Sight Medical Products stock. The stock was acquired at an average price of $1.71 per share, with a total value of $38,919.60.

NASDAQ EYES traded down $0.06 during trading hours on Friday, reaching $1.56. The company’s stock had a trading volume of 140,336 shares, compared to its average volume of 174,629. The firm has a market cap of $108.66 million, a PE ratio of -2.64 and a beta of 3.08. Second Sight Medical Products Inc has a 52 week low of $0.99 and a 52 week high of $2.58.

Second Sight Medical Products (NASDAQ:EYES) last issued its quarterly earnings data on Tuesday, August 7th. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. The business had revenue of $1.91 million during the quarter, compared to analyst estimates of $2.21 million. Second Sight Medical Products had a negative net margin of 418.82% and a negative return on equity of 432.45%. analysts predict that Second Sight Medical Products Inc will post -0.58 EPS for the current year.

A number of research analysts recently issued reports on EYES shares. Zacks Investment Research upgraded shares of Second Sight Medical Products from a “hold” rating to a “buy” rating and set a $2.25 price objective for the company in a report on Thursday, May 17th. HC Wainwright set a $5.00 price objective on shares of Second Sight Medical Products and gave the company a “buy” rating in a report on Tuesday, May 15th. Finally, ValuEngine upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. Glassman Wealth Services acquired a new stake in Second Sight Medical Products Inc (NASDAQ:EYES) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 72,366 shares of the medical device company’s stock, valued at approximately $139,000. Glassman Wealth Services owned about 0.12% of Second Sight Medical Products at the end of the most recent reporting period. 10.68% of the stock is currently owned by institutional investors and hedge funds.

About Second Sight Medical Products

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Read More: Hedge Funds – Risk or Reward?

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.